Smoking and therapeutic response to clozapine in patients with schizophrenia
Smoking and therapeutic response to clozapine in patients with schizophrenia
复制标题
DOI：
10.1016/s0006-3223(98)00377-1
复制
发表时间：
1999-07-01
影响因子：
10.6
通讯作者：
Wilson, WH
中科院分区：
文献类型：
--
作者：
McEvoy, JP;Freudenreich, O;Wilson, WH
背景：在精神分裂症患者中，70%到80%的人吸烟。尼古丁可以纠正许多精神分裂症患者的某些信息处理和认知精神运动缺陷。氯氮平，但不是传统的抗精神病药物，已经被证明可以纠正其中的一些缺陷。方法：我们评估了70例难治性精神分裂症患者(55名吸烟者和不吸烟者)在接受常规抗精神病药物治疗时和改用氯氮平后的精神病理学和吸烟情况。结果：吸烟者对氯氮平的治疗反应显著高于不吸烟者。吸烟者在接受氯氮平治疗时吸烟较少。结论：某些精神分裂症患者存在对尼古丁或氯氮平有效的病理生理机制。(C)1999年生物精神病学学会。
Background: Of patients with schizophrenia, 70 to 80% smoke. Nicotine corrects certain information processing and cognitive psychomotor deficits seen in many patients with schizophrenia. Clozapine, but not conventional antipsychotics, has been shown to correct some of these deficits.Methods: We assessed psychopathology and smoking in 70 patients with treatment refractory schizophrenia (55 smokers and IS nonsmokers) at baseline when they were receiving conventional antipsychotics and again after they were switched to clozapine.Results: Smokers showed significantly greater therapeutic response to clozapine than nonsmokers. Smokers smoked less when treated with clozapine than when treated with conventional antipsychotics.Conclusions: Certain patients with schizophrenia have contributing pathophysiologic mechanisms that respond favorably to either nicotine or clozapine, (C) 1999 Society of Biological Psychiatry.